Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal

Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma in a deal worth up to $385 million. Sutro will receive an upfront payment of $40 million and be eligible for $345 million in milestone payments.